Blueprint Sees Blockbuster Potential For Ayvakit In Systemic Mastocytosis With ISM Nod

 
• By Alaric DeArment
  
Blueprint Medicines announced the approval of Ayvakit in indolent systemic mastocytosis • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip